Health
China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials: journal – Reuters
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
BEIJING (Reuters) – A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The candidate has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Sinopharm is testing the potential vaccine in the United Arab Emir…
-
Noosa News16 hours agoFamily pleads for help after 17-year-old Pheobe Bishop disappears in Bundaberg before flight
-
Business17 hours agoASX 200 lifts on the RBA’s latest interest rate call
-
Noosa News20 hours agoNo conviction recorded for teen behind attack on Peter Dutton’s office
-
Noosa News20 hours ago‘They’re not taking the concerns of women seriously’